Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antineoplastic agent |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 1998 |
| gptkbp:ATCCode |
L01BC06
|
| gptkbp:brand |
gptkb:Xeloda
|
| gptkbp:CASNumber |
154361-50-9
|
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to capecitabine |
| gptkbp:developedBy |
gptkb:Hoffmann-La_Roche
|
| gptkbp:eliminationHalfLife |
0.75 hours
|
| gptkbp:hasMolecularFormula |
C15H22FN3O6
|
| https://www.w3.org/2000/01/rdf-schema#label |
capecitabine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits DNA synthesis
converted to 5-FU in tumor tissue |
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:prodrugOf |
gptkb:5-fluorouracil
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:hand-foot_syndrome
nausea vomiting diarrhea fatigue neutropenia |
| gptkbp:usedFor |
gptkb:cancer
colorectal cancer gastric cancer |
| gptkbp:bfsParent |
gptkb:Tukysa
|
| gptkbp:bfsLayer |
6
|